How the Government Can Prevent Individuals from Using Wealth to Cut the Vaccine Line
There are several ways government officials can combat the wealth problem without sacrificing the speed at which vaccines are administered.
vaccines
-
Read more: How the Government Can Prevent Individuals from Using Wealth to Cut the Vaccine Line -
Read more: How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing? How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing?
The difficult manufacturing issues involved in the therapeutic antibody context, and what might be done to address them.
-
Read more: Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19? Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19?
The rapid development of therapeutic antibodies is a triumph of biomedical innovation. But they won’t help unless they make it to patients.
-
Read more: What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout? What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout?
In this post we explain what went wrong and how policymakers can correct course for COVID-19 and avoid such disasters in the future.
-
Read more: From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization
The history of EUA involves fundamental questions about the role of public officials, scientific expertise, and administrative norms in times of crisis.
-
Read more: Is Israel Trading Medical Information for Vaccines? Ethical and Legal Considerations Is Israel Trading Medical Information for Vaccines? Ethical and Legal Considerations
Israel’s rich health databases are probably the reason why Pfizer agreed to a deal to expedite deliveries of its vaccine.
-
Read more: Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts
Given the potential legal challenges policymakers may face, legislation to remedy the COVID-19 educational crisis must be carefully drafted.
-
Read more: How Can Policymakers Encourage COVID-19 Vaccine Trials for Children? How Can Policymakers Encourage COVID-19 Vaccine Trials for Children?
We explain why COVID-19 vaccines are only just starting to be tested in children and what policymakers can do to spur pediatric vaccine trials.
-
Read more: COVID-19 and the FDA Emergency Use Authorization Power COVID-19 and the FDA Emergency Use Authorization Power
This blog post provides an overview of the FDA’s emergency authorization powers and analyzes the extent of their usage in the COVID-19 pandemic.
-
Read more: How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process? How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process?
Pharmaceutical companies are now also engaging the public themselves in an attempt to build trust in their products.
